Nonprofit Funders Unite to Accelerate Fight Against Batten Disease, Granting $1 Million for Research to Develop Treatment and Cure

AUSTIN, TEXAS (February, 2013) The Batten Disease Support and Research Association (BDSRA) and Beyond Batten Disease Foundation (BBDF), working together in close partnership with more than 20 other nonprofits around the world, today announced grants totaling almost $1 million for research to develop treatments and a cure for Batten disease.

Batten disease is a rare and fatal neurodegenerative disorder that strikes infants, children and adults. There is no known treatment or cure. Those born to parents who carry gene mutations for Batten disease are at risk to inherit the condition which can cause vision loss and seizures, progressively impairs cognitive and motor capacities, and ultimately results in death.

Funding for research has been challenging due to the rare nature of the disease. The 2013 grants represent the largest Batten disease research collaboration to date. The new grants will support nine high-value projects at universities and institutes in the United States, Great Britain, Germany, Israel and New Zealand. The goals of these projects include:

Organizations pooling their funds for the nearly $1 million in grants include BDSRA, BBDF, Hope for Bridget, Blake’s Purpose, Our Promise to Nicholas, Fight for Nicholas, Biomarin, LLC, and Noah’s Hope – all based in the United States – along with Germany’s NCL-Stiftung and the United Kingdom’s Batten Disease Family Association. Together these organizations are funding basic discovery to identify drug targets, translate those discoveries into treatment, and prepare for clinical trial success. Expanding, improving and connecting registries will result in the world’s largest, clinically and genetically best characterized set of Batten disease patients. Exploring multiple approaches to identify biomarkers capable of measuring the efficacy of potential drugs for treating Batten disease will ensure clinical trial success.

“We are so proud of the accomplishments of all the organizations and dedicated scientists involved in this unprecedented, international effort to identify and fund research for curing this devastating disease,” said Margie Frazier, PhD, executive director of the BDSRA. “This is a great example of the whole being so much greater than the sum of its parts.”

The world’s leading Batten disease nonprofit organizations are uniting to pool funds and expertise to evaluate grant proposals based on a state-of-the-art scientific merit review process that reflects the highest standards associated with the U.S. National Institutes of Health, the European Research Council and industry-standard drug discovery processes.

“We’ve crossed a major milestone in the fight against Batten disease,” said Craig Benson, founder and CEO of Beyond Batten Disease Foundation. “Through this type of global collaboration, we can take an even more strategic approach and apply both greater rigor and resources to our work, ensuring that the most important research to treat and cure this horrific illness gets funded.”

The newly funded work will be completed at University of Texas Southwestern Medical Center, Yale University, University of Iowa and University of Medicine and Dentistry in the US; Weizmann Institute of Science in Israel; King’s College London in the United Kingdom; University Medical Center Hamburg-Eppendorf in Germany; and Lincoln University in New Zealand.

Other nonprofits joining Batten Disease Support and Research Association and Beyond Batten Disease Foundation in the fight against Batten Disease include: Catherine’s Hope for a Cure, Drew’s Hope, Hayden’s Hope, Luke and Rachel Batten Foundation, Mary Payton’s Miracle Foundation, Melissa Froio Foundation, Partnering for Cures and Taylor’s Tale in the US; Jasper Against Batten in the US and Netherlands; Beat Batten! in the Netherlands; Bee for Batten’s in Ireland; ContactPuntNCL in Belgium; NCL-Gruppe Deutschland in Germany; and Norsk Spielmeyer-Vogt Forening in Norway.

About The Batten Disease Support and Research Association

The Batten Disease Support and Research Association is the major support and research organization in North America for families who have children with the disease. Founded in 1987, the association promotes and funds research nationally and internationally, provides family services and advocacy, fosters awareness and education with the scientific, medical and caregiving community, and coordinates networks for diagnosis, medical referrals, genetic testing, and counseling. The first research grant from BDSRA was awarded in 1992 and, since then, more than $6 million in funding has been awarded. BDSRA is the largest source of private funding for family support and research into the disease. For more information, visit www.bdsra.org.

About Beyond Batten Disease Foundation

Beyond Batten Disease Foundation works to cure and prevent juvenile Batten disease, a rare, inherited neurological disorder that strikes young children; first causing vision loss and seizures, then cognitive and motor impairment, and ultimately, death by the late teens or 20s. The foundation raises funds for research, and is leading the development of an easy, inexpensive, groundbreaking blood test to detect gene mutations that cause Batten disease as well as 600 other rare, serious and often fatal, childhood ailments. For more information, visit www.beyondbatten.org.

# # #

Contact:
Danielle M Kerkovich, PhD
Scientific Officer | Batten Disease Support and Research Association
Principal Scientist | Beyond Batten Disease Foundation
info@beyondbatten.org
202-812-6462
www.bdsra.org
www.beyondbatten.org

Faster DNA Testing Helps Diagnose Disease in NICU Babies

by Alice Park on healthland.time.com

Fifty hours. That’s how long it now takes to decode and interpret a newborn baby’s genome — an undertaking that used to take weeks, or even months. And those two days can mean the difference between life and death for a critically ill infant.

In a paper published in the journal Science Translational Medicine, researchers led by Stephen Kingsmore, director of the Center for Pediatric Genomic Medicine at Children’s Mercy Hospital, describe a new genetic test that can rapidly screen the DNA of babies in the neonatal intensive care unit (NICU) for about 3,500 diseases known to be linked to single-gene mutations. Of these, doctors can treat about 500.

Up to a third of babies admitted to the NICU have a genetic disease. But many newborns are not diagnosed properly and may therefore miss the opportunity for a potentially life-saving therapy. Many of the symptoms of such genetic diseases are both general and shared by many different conditions, which makes them difficult to diagnose; what’s more, many of the genetic conditions in question are rare, so most physicians, even NICU specialists, may not be familiar them or unable to recognize their symptoms. Currently used genetic tests are also too expensive and time-consuming to be clinically useful; because the tests can take weeks, or sometimes months, most NICU babies will have either gone home or died by the time the results are ready.

So Kingsmore and his colleagues collaborated with Illumina, a manufacturer of gene-sequencing machines, to shorten the time it takes to both decode an entire genome and generate a clinically useful analysis of that sequencing. Thanks to recent advances in the ability to break up and re-knit DNA, the company was able to sequence the 3 billion base pairs of the genome in just 27 hours — down from weeks.

But decoding a genome is only half of the challenge. Words in a book don’t make sense unless they are put together in a grammatically sensible way, and similarly, DNA is meaningless unless it’s analyzed in the context of genes, which in turn are connected to human functions or conditions. So for two years, Kingsmore’s team worked on special software designed to help doctors use genetic information to make accurate diagnoses and guide ill babies to the right treatment.

The software simplifies and standardizes the often complex process of diagnosis, by allowing doctors to click on the symptoms they see in newborns; the program then puts together a list of the genes that might be most likely to be at fault. Doctors can then compare these genetic suspects to the newborn’s sequenced genome to see if any of the same genes are mutated; if they are, they can pinpoint a diagnosis.

 “There is a phenomenal need for more accurate and faster diagnosis in the NICU,” says Kingsmore, adding that “this is a setting where we know that giving treatments is one of the most effective things we can do in medicine from the cost standpoint, since these patients have 65 to 70 years of life to live out.”

Of the 4 million babies born in the U.S. each year, about 1 in 20 are admitted to the NICU for potentially life-threatening reasons, and about 30% of those are for inherited genetic diseases. Accurately diagnosing these babies can help them get effective treatments that can improve their quality of life and in many cases save them from an early death.

Using the combination of the prototype Illumina sequencer and the new software, Kingsmore and his team have sequenced 15 babies’ genomes as part of their study, and have seen how powerful the screening can be. In the case of Pompe disease, for example, in which a genetic abnormality leaves babies deficient in an enzyme that breaks down glycogen (a form of sugar the body uses for energy), the genetic sequencing can pick up the mutation and alert the doctor to begin giving the baby the enzyme, which drug companies make as a therapy. The treatment can keep infants off ventilators and offset some of the heart and muscle damage that Pompe disease causes.

Newborns with Menkes disease can also benefit from the screening; their bodies cannot break down copper, so they need injections of the mineral. Without a genetic screen to confirm the deficiency, however, doctors wouldn’t know to treat them. And giving excess copper to babies who aren’t deficient can be dangerous, leading to copper poisoning, with diarrhea, convulsions and liver failure.

Timing is critical in the NICU, and Kingsmore says the ability to get an accurate diagnosis in two days can lead to dramatic improvements in survival and quality of life for many NICU babies. For now, the screening is only available on an experimental basis, as part of ongoing research, but he anticipates that such genetic testing will become ubiquitous as the price of sequencing continues to drop. Next year, he’s planning to offer the testing to other hospitals that will courier DNA samples to Children’s Mercy. “We expect better outcomes and broader benefits to follow from doing this,” he says. And hopefully many more lives saved.

http://healthland.time.com/2012/10/04/good-news-for-nicu-babies-faster-dna-testing-for-more-accurate-diagnoses/

Beyond the Valley of Death: A Strategic Path Toward a Cure for Batten disease

Beyond Batten Disease Foundation is spearheading a unique, cohesive strategy that incorporates independent scientific resources and collaborations with related funding organizations to drive research into Batten Disease. Watch the following video to see how Beyond Batten Disease Foundation is working with academia, the pharmaceutical industry, and government agencies to cross the “Valley of Death” between initial scientific discoveries and meaningful progress toward treatments and cures.

Featured Fundraiser


On Sunday October 21st, 25 girls gathered in Grace and Brynley May’s front yard to show support for one of their school mates. Each girl baked beautifully decorated trays of delicious cookies, cupcakes and brownies and delivered them to tables lining the front yard. Fourth grade girls welcomed neighbors along the sidewalk and flagged down passing cars with homemade signs until every baked goodie was sold.

The girls awarded Beyond Batten Disease Foundation $1,000 with their loving and supportive efforts to help a friend. Thank you so much to all who participated, and especially Grace and Brynley for organizing the bake sale and offering their home.

A Mother’s Story

With the holidays approaching, the children and I have decided to decorate our front yard with characters from our favorite Christmas story…….Dr. Seuss’ How the Grinch Stole Christmas. Twelve years ago, my brother, John, made a Grinch who sat on the front porch at Christmas, and I remember all of the children being fixated on every detail, fascinated with his yellow eyes, bright green skin, and long fingernails. Every wrinkle of his face was animated with a grin that held the awful thought of his plot to end Christmas by stealing it away from the Whos. Every child imagined what it would be like to wake up with no presents or toys, and the Grinch would finally be satisfied that he had put an end to the noise and commotion of Christmas.

Read More

Austin Golfers Join Fight Against Batten Disease at Fourth Annual Hope on the Green Tournament

AUSTIN, TX — Austin-area golfers are getting ready to take a swing at juvenile Batten disease during the Fourth Annual Brake Specialists Plus “HOPE on the Green” Charity Golf Tournament on Friday, October 19 at Grey Rock Golf Club.

The popular tournament will help raise critically needed funds for Beyond Batten Disease Foundation which works to eradicate juvenile Batten disease, a rare, inherited and fatal neurodegenerative disorder that occurs in young children.

“Hope on the Green is a great way for Central Texas golfers to enjoy a round of golf while also helping to save children’s lives,” said Jamey Whitlock, Executive Vice President, Brake Specialists Plus Total Car Care, title sponsor of the tournament. “Proceeds from the event help the foundation to continue funding live-saving research around the world to treat, cure and prevent this devastating illness.”

Although the tournament is expected to sell out again this year, registration currently remains open for foursomes as well as individual players. Participants will enjoy a fun-packed afternoon and evening at one of the region’s best golf facilities. Activities will include: lunch catered by Benji’s Cantina and dinner provided by Grey Rock Golf Club; 18 holes of golf on a stunning Texas Hill Country course designed by renowned golf architect Jay Moorish; putting, chipping, longest drive and hole-in-one contests for prizes such as TaylorMade and Titleist clubs and bags; a live auction, including memorabilia autographed by well-known sports and music personalities; and live music following tournament play.

Juvenile Batten disease occurs when parents who unknowingly carry the gene mutation for the disorder both pass it onto their offspring. Children are diagnosed when they become symptomatic, usually between the ages of 5 and 9. The illness causes seizures and progressive vision loss leading to blindness. The condition eventually becomes mentally and physically incapacitating and is fatal by the late teens or early 20s.

Because Batten disease is so uncommon, there is very little government support for research. Beyond Batten Disease Foundation funds a growing number of research initiatives in the United States and abroad to develop a treatment and cure. The foundation also has led development of a rare disease genetic test to diagnose and prevent not only Batten disease, but also more than 600 other serious – often fatal – inherited, childhood illnesses.

“All of us fighting Batten disease greatly appreciate everyone who participates in Austin’s Hope on the Green tournament – Jamey, the Brake Specialists’ team and, of course, all the golfers who come out to play,” said Craig Benson, who co-founded the foundation with his wife in 2008 after their young daughter was diagnosed with Batten disease. “The event is an important fundraiser and also helps us raise awareness of and galvanize ongoing support for our cause.”-

In recent years, the foundation has underwritten some of the world’s most promising juvenile Batten disease research. This includes funding a team of researchers at the Jan and Dan Duncan Neurological Research Institute at Houston’s renowned Texas Children’s Hospital. The team has identified drug compounds that may improve brain function in children with Batten disease and currently is analyzing disease models to study long-term effects on progression of the illness. The foundation also has brought in regulatory consultants to partner with the researchers at Texas Children’s Hospital in developing a path to FDA approval for a human clinical trial of the drugs.

Other foundation-funded projects include a partnership with the American Brain Foundation to create the first clinical research fellowship in juvenile Batten disease; research support at Italy’s Telethon Institute of Genetics and Medicine using robotic technology to screen hundreds of drugs for their potential to treat Batten disease; and additional research at London’s King’s College and the University of Iowa to learn more about Batten disease cell function.

Nearly 700 Expected At Sept. 15 “HOPE Under the Stars Gala” In The Woodlands to Help Fight Juvenile Batten Disease

THE WOODLANDS, TX — Nearly 700 people are expected to attend one of the Houston area’s most important fundraisers on September 15, the 4th annual HOPE Under the Stars Gala benefiting the Will Herndon Fund for Juvenile Batten Disease Research (WHF).

Will HerndonThe evening event at The Woodlands Resort and Conference Center will generate critically needed funds for research to develop a treatment and cure for juvenile Batten disease, a rare, fatal, neurodegenerative disorder that affects children.

Attendees of the “Texas chic”-themed party will enjoy a night of great entertainment including mechanical bull riding, professional artist sketches, dancing and live music by The Buck Town All-Stars, the nine-piece, New Orleans-based band famous for its energizing mix of rock, soul, funk, R&B and Crescent City classics. Additionally, there will be a photo booth, casino tables, a raffle, and both live and silent auctions for fabulous items. Tickets and sponsorship opportunities are still available through the WHF website or by calling 409.454.9330.

Juvenile Batten disease is a rare but devastating illness that typically appears between the ages of five and 10. Early symptoms include vision loss leading to total blindness and also seizures. As the disease progresses, it diminishes cognitive and motor capacities – to the point where affected youngsters require 24-hour care – and ultimately causes death during the late teen years or early 20s.

Because juvenile Batten disease is uncommon – it occurs in two to four of every 100,000 children born in the United States – there is very little government funding for research to find a treatment and cure. So in August 2009, after learning that their then six-year-old son, Will, had Batten disease, Missy and Wayne Herndon of The Woodlands started the Will Herndon Fund. WHF is a directed fund of Beyond Batten Disease Foundation, launched a year earlier to raise awareness of and support research to eradicate the malady. The foundation also has been leading development of a test to detect the gene mutations that cause Batten disease as well as 600-plus other serious, often fatal, childhood conditions.

“As we approach this year’s gala, which is drawing a record number of attendees, we are more heartened than ever by the ongoing support of our friends and neighbors in the Greater Woodlands community,” said Missy Herndon. “Every dollar we raise advances the foundation’s life-saving work and gives new hope to families affected by Batten disease.”

In recent years, WHF has helped fund many of the world’s most promising research initiatives focused on juvenile Batten disease. This includes funding a team of researchers at the Jan and Dan Duncan Neurological Research Institute at Houston’s renowned Texas Children’s Hospital. The team has identified a drug combination that may improve brain function in children with Batten disease and currently is analyzing disease models to study long-term effects on progression of the illness. This includes funding a team of researchers at Houston’s renowned Texas Children’s Hospital which has identified a drug combination that may improve brain function in children with Batten disease. Currently, the team is analyzing disease models to study the long-term effects of this drug on the progression of the disease. Additionally, with funds raised from last year’s HOPE Under the Stars gala, WHF recently brought in regulatory consultants to partner with the researchers in developing a path to FDA approval for a human clinical trial of the drug.

Other WHF-funded projects include a partnership with the American Brain Foundation to create the first clinical research fellowship in juvenile Batten disease; research support at Italy’s Telethon Institute of Genetics and Medicine using robotic technology to screen hundreds of drugs for their potential to treat Batten disease; and additional research at London’s King’s College and the University of Iowa to learn more about Batten disease cell function. Each of these projects is part of WHF’s strategic plan to accelerate research for developing treatments and a cure for juvenile Batten disease.

About The Will Herndon Fund and Beyond Batten Disease Foundation

The Will Herndon Fund is a directed fund of the Beyond Batten Disease Foundation which works to cure and prevent Batten disease, a rare, inherited neurological disorder that strikes young children, first causing vision loss and seizures, then cognitive and motor impairment, and ultimately death during the late teen years or early 20s. The foundation raises funds for research and is leading development of an easy and inexpensive, groundbreaking blood test to detect the gene mutations that cause Batten disease as well as over 600 other rare but serious and often fatal childhood ailments. For more information, visit www.beyondbatten.org.

Photos: Above–Will Herndon, age 9, was diagnosed with juvenile Batten disease in 2009; Below–The Will Herndon Fund supports important juvenile Batten disease research at the Jan and Dan Duncan Neurological Research Institute at Houston’s renowned Texas Children’s Hospital.

A Mother’s Story

by guest columnist Missy Herndon

Three years ago, Missy and Wayne Herndon received the shocking news that their then 6 year old son, Will, had been diagnosed with Batten disease. Like the Bensons, the Herndons responded with a “knowing” that they had to do something to make a difference. Shortly after Will’s diagnosis, the Herndons created the Will Herndon Fund and joined BBDF to collaborate their efforts to fund research to find a treatment or a cure for their children.

The Torch of Hope

“For I know the plans I have for you,” declares the Lord, “Plans to prosper you and not to harm you, plans to give you hope and a future.” Jeremiah 29:11

Read More
1 20 21 22 23 24 29